![](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/05\/9047dad7436323a1_featured.png\"\/)
\n
\n <\/p>\n
\n
\n
<\/p>\n
\n
\n
<\/p>\n
<\/p>\n
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.<\/strong> M\u00f6lnlycke Health Care (\u201cM\u00f6lnlycke\u00ae\u201d), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world\u2019s fastest-growing wound care markets. The joint venture, majority-owned by M\u00f6lnlycke, will integrate the two companies\u2019 wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China.<\/p>\n China’s wound care market continues to expand, with the advanced wound dressing segment valued at approximately EUR 380 million (RMB 3 billion), driven by rising chronic disease prevalence, an ageing population and increasing demand for advanced treatment solutions.1\u00a0As a first mover in establishing a joint venture of this kind in the Chinese wound care market, M\u00f6lnlycke and Zhende Medical see this strategic collaboration as an opportunity to help accelerate the evolution of China\u2019s wound care landscape toward more advanced standards of treatment.<\/p>\n By combining product strengths, distribution reach and deep clinical know-how, the joint venture \u2014 to be named M\u00f6lnlycke Zhende (Shanghai) Medical Technology Co Ltd (\u201cM\u00f6lnlycke Zhende\u201d) \u2014 unites two complementary organisations with a shared ambition: to build a stronger, more competitive market access model and drive long-term growth. More specifically, it brings together:<\/p>\n For M\u00f6lnlycke, the joint venture advances its localisation strategy by combining global expertise with local capabilities, accelerating access to advanced wound care solutions, more effectively addressing customer needs in China and capturing long-term growth opportunities in a rapidly evolving market.<\/p>\n Guillaume Joucla, Interim CEO, M\u00f6lnlycke Health Care<\/strong>, says, \u201cThis joint venture represents an important milestone in the growth journey of both M\u00f6lnlycke and Zhende Medical. By joining forces, we are strengthening our presence in China, expanding our wound care portfolio and significantly enhancing our go-to-market capabilities to better serve more customers and patients.\u201d <\/p>\n For Zhende Medical, the joint venture represents an opportunity to deepen collaboration with a global provider of premium wound care solutions and advance its product portfolio to ensure relevance and value for current and future market needs.<\/p>\n Dasheng Xu, <\/strong>Board Director, Executive Deputy General Manager<\/strong> and <\/strong>Executive President<\/strong> of Zhende Medical<\/strong>, says, \u201cThis partnership demonstrates the strength, resilience and long\u2011term ambition of both companies. By combining our complementary capabilities and deep market knowledge, we are well positioned to meet the growing demand for advanced wound care solutions in China.\u201d<\/p>\n Operating as a standalone entity, M\u00f6lnlycke Zhende will be majority owned by M\u00f6lnlycke, with headquarters in Shanghai. It is expected to be operational during Q3 2026 and will initially focus on the sales and distribution of both companies\u2019 advanced wound care products, with potential to expand into co-development of products over time. Manufacturing will be supported through both companies\u2019 existing sites. The joint venture is committed to be compliant with M\u00f6lnlycke\u2019s and Zhende Medical\u2019s global sustainability commitments, setting the standard for operations and business conduct.<\/p>\n -Ends-<\/p>\n For more information, please contact<\/strong>:<\/strong><\/p>\n M\u00f6lnlycke<\/strong><\/p>\n Jamie Smith Brunswick Group Zhende Medical<\/strong><\/p>\n Wang Zhihong About M\u00f6lnlycke<\/strong><\/p>\n M\u00f6lnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. M\u00f6lnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, M\u00f6lnlycke is owned by Investor AB and headquartered in Sweden.\u00a0www.molnlycke.com<\/a><\/p>\n About <\/strong>Zhende Medical<\/strong><\/p>\n Established in1994, Zhende Medical Co., Ltd. a Chinese A-share listed company (“Zhende Medcial”, stock code: 603301.SH), is a leading supplier of medical supplies and protective equipment from China.<\/p>\n We make healthy life within reach. Our product lines cover various usage scenarios and provide one-stop product solutions. Currently, the products and solutions are used daily by hospitals, medical institutions and patients specialized markets such as OR, protective products, and pressure treatment.<\/p>\n ===<\/p>\n
Tags:<\/strong><\/p>\n
\n
Media Relations Manager
E-mail jamie.smith@molnlycke.com<\/a><\/p>\n
E-mail molnlyckemedia@brunswickgroup.com<\/a> <\/p>\n
Product Strategy & Branding Director
E-mail wzh@zhende.com<\/a><\/p>\n
\n
\n
\n
<\/p>\n
\n
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
First-of-its-kind joint venture combines the two companies\u2019 wound care portfolios to deliver a…\n","protected":false},"author":2,"featured_media":497491,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[381,18,135,475,474,19,17,93268,12585,55233],"class_list":["post-497490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-china","tag-eire","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-joint-venture","tag-medtech","tag-wound-care"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116618527819824710","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/497490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=497490"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/497490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/497491"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=497490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=497490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=497490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}